• -
  • English
  • Japanese
市場調查報告書
商品編碼
955319

乾燥症(修格蘭氏症候群):流行病學預測(2030年)

Sjogren's syndrome - Epidemiology Forecast - 2030
出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

乾燥症(修格蘭氏症候群)(SS)，是外分泌腺，主要是唾液腺和淚腺，再加上鼻子，上呼吸道，中咽，及女性的情況有引起陰道發炎，有特定原因的慢性自體免疫疾病。乾燥症(修格蘭氏症候群)的患者，有各種前兆和症狀，需要通知各種專門領域的醫生，疾病臨床症狀的目前方面，修訂的分類標準，及目前治療選擇。

本報告提供乾燥症(修格蘭氏症候群)(SS)的流行病學預測記載，各確診的盛行率，性別、各類型、各重病度特定的案例，目前治療慣行，主要7個國家(美國，德國，法國，義大利，西班牙，英國，日本)的流行病學患者人口等資訊。

目錄

第1章 主要洞察

第2章 乾燥症(修格蘭氏症候群)(SS):流行病學概要

  • 2017年的SS的患者佔有率分佈
  • 2030年的SS的患者佔有率分佈

第3章 組織

第4章 摘要整理

第5章 疾病概要

  • 簡介
  • 乾燥症(修格蘭氏症候群)的分類
  • 徵兆與症狀
  • 病因
  • 乾燥症(修格蘭氏症候群)的生物標記
  • 乾燥症(修格蘭氏症候群)的診斷
    • 鑑別診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的乾燥症(修格蘭氏症候群)的整體診斷患者數
  • 乾燥症(修格蘭氏症候群)的各國流行病學
  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 目前治療慣行

  • 對修格蘭氏症的美國的治療指南
  • 證據為基礎醫療的診療指南(美國，歐洲聯盟，日本)

第8章 潛在的需求

第9章 SWOT分析

第10章 KOLview

第11章 附錄

第12章 報告的調查手法

第13章 DelveInsight的服務內容

第14章 免責聲明

第15章 關於DelveInsight

目錄
Product Code: DIEI0342

DelveInsight's 'Sjogren's syndrome (SS)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the Sjogren's syndrome, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Sjogren's syndrome (SS) Disease Understanding

Sjogren's syndrome (SS) is a chronic autoimmune disease with a specific predisposition for causing inflammation of the exocrine glands, predominantly the salivary and lacrimal glands but also including the nose, upper respiratory tract, and oropharynx and, in women, the vagina. In this, the immune system inappropriately attacks various cells that leads to activation of the various pathway, which results in inflammation. The main consequence of this inflammation is the development of sicca symptoms due to damage to salivary and tear glands, such as dryness of the mucosal surfaces, principally in the mouth and eyes. Increased levels of cytokines and chemokines and autoantibodies expressed by the epithelium of the exocrine glands (such as the salivary and lacrimal glands) lead to chronic inflammation and the eventual loss of their physiological functions.

Due to the wide variety of signs and symptoms, patients with Sjogren's syndrome may see a diverse range of healthcare practitioners, including family physicians, ophthalmologists, ENT specialists, and dentists, at the first consultation. Thus, physicians of various specialties must be informed about current aspects of clinical manifestations of the disease, the revised classification criteria, and current treatment options.

Sjogren's syndrome (SS) Epidemiology

The Sjogren's syndrome epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Sjogren's syndrome epidemiology segmented as the Diagnosed Prevalent Cases of Sjogren's syndrome, Gender-Specific Cases of Sjogren's syndrome, Type-Specific Cases of Sjogren's syndrome, Severity-Specific Cases of Sjogren's syndrome. The report includes the Prevalent scenario of Sjogren's syndrome symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Sjogren's syndrome (SS) Epidemiology

The epidemiology segment also provides the Sjogren's syndrome (SS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of Sjogren's syndrome in 7MM countries was estimated to be 3,179,223 cases in 2017.

  • As per the estimates, the United States has the highest Prevalent population of Sjogren's syndrome
  • Among the EU5 countries, the UK had the highest Prevalent population of Sjogren's syndrome. On the other hand, Spain had the lowest Prevalent population with 197,008 cases in 2017.

Scope of the Report:

  • Sjogren's syndrome (SS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • Sjogren's syndrome (SS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Sjogren's syndrome (SS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Sjogren's syndrome (SS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Sjogren's syndrome
  • The report provides the segmentation of the Sjogren's syndrome (SS) epidemiology by Prevalent Cases of Sjogren's syndrome (SS) in 7MM
  • The report provides the segmentation of the Sjogren's syndrome (SS) epidemiology by Type-specific, Gender-specific and Severity-specific Prevalent Cases of Sjogren's syndrome (SS) in 7MM

Report Highlights:

  • 11-Year Forecast of Sjogren's syndrome (SS) epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Sjogren's syndrome (SS)
  • Prevalent Cases according to segmentation: Type-specific Prevalence of Sjogren's syndrome (SS), Gender-specific Prevalenceof Sjogren's syndrome (SS), Severity-specific Prevalenceof Sjogren's syndrome (SS)

KOL- Views

We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Sjogren's syndrome (SS)?
  • What are the key findings pertaining to Sjogren's syndrome (SS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Sjogren's syndrome (SS) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burden, and unmet needs of Sjogren's syndrome?
  • What are the currently available treatments for Sjogren's syndrome?

Reasons to buy:

The Sjogren's syndrome (SS) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Sjogren's syndrome (SS) market
  • Quantify patient populations in the global Sjogren's syndrome (SS) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Sjogren's syndrome (SS) therapeutics in each of the markets covered
  • Understand the magnitude of Sjogren's syndrome (SS) population by its Prevalence cases
  • Understand the magnitude of Sjogren's syndrome (SS) population by its Etiology-specific cases
  • The Sjogren's syndrome (SS) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Sjogren's syndrome (SS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

The study conducted by Maciel et al., (2017), titled "Prevalence of Primary Sjogren's Syndrome in a Population-Based Cohort in the United States" is the first population-based study performed in the US and study reports the first prevalence trends of Sjogren's syndrome.

A total of 106 patients with a physician-based diagnosis of pSS were living in 2015. Among these, 86% were female, with a mean age of 64.6 (15.2) years and disease duration of 10.5 (8.4) years. Most patients (98%) complained of dry mouth, dry eyes, or both.

Table of Contents

1. Key Insights

2. Sjogren's Syndrome (SS): Epidemiology Overview at a Glance

  • 2.1. Patient Share (%) Distribution of SS in 2017
  • 2.2. Patient Share (%) Distribution of SS in 2030

3. Organizations

4. Executive summary

5. Disease Overview: Sjogren's syndrome

  • 5.1. Introduction
  • 5.2. Classification of Sjogren's Syndrome
  • 5.3. Signs and Symptoms
  • 5.4. Etiology
  • 5.5. Pathogenesis
  • 5.6. Biomarkers in Sjogren's Syndrome
  • 5.7. Diagnosis of Sjogren's Syndrome
    • 5.7.1. Differential Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Diagnosed Prevalent Patient Population of Sjogren's Syndrome
  • 6.3. Country Wise-Epidemiology of Sjogren's syndrome
  • 6.4. United States
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Diagnosed Prevalent Cases of Sjogren's syndrome in the United States
    • 6.4.3. Gender-Specific Cases of Sjogren's syndrome in the US
    • 6.4.4. Type-Specific Cases of Sjogren's syndrome in the US
    • 6.4.5. Severity-Specific Cases of Sjogren's syndrome in the US
  • 6.5. Germany
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Germany
    • 6.5.3. Gender-Specific Cases of Sjogren's syndrome in Germany
    • 6.5.4. Type-Specific Cases of Sjogren's syndrome in Germany
    • 6.5.5. Severity-Specific Cases of Sjogren's syndrome in Germany
  • 6.6. France
    • 6.6.1. Assumptions and Rationale
    • 6.6.2. Diagnosed Prevalent Cases of Sjogren's syndrome in France
    • 6.6.3. Gender-Specific Cases of Sjogren's syndrome in France
    • 6.6.4. Type-Specific Cases of Sjogren's syndrome in France
    • 6.6.5. Severity-Specific Cases of Sjogren's syndrome in France
  • 6.7. Italy
    • 6.7.1. Assumptions and Rationale
    • 6.7.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Italy
    • 6.7.3. Gender-Specific Cases of Sjogren's syndrome in Italy
    • 6.7.4. Type-Specific Cases of Sjogren's syndrome in Italy
    • 6.7.5. Severity-Specific Cases of Sjogren's syndrome in Italy
  • 6.8. Spain
    • 6.8.1. Assumptions and Rationale
    • 6.8.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Spain
    • 6.8.3. Gender-Specific Cases of Sjogren's syndrome in Spain
    • 6.8.4. Type-Specific Cases of Sjogren's syndrome in Spain
    • 6.8.5. Severity-Specific Cases of Sjogren's syndrome in Spain
  • 6.9. United Kingdom
    • 6.9.1. Assumptions and Rationale
    • 6.9.2. Diagnosed Prevalent Cases of Sjogren's syndrome in the United Kingdom
    • 6.9.3. Gender-Specific Cases of Sjogren's syndrome in the United Kingdom
    • 6.9.4. Type-Specific Cases of Sjogren's syndrome in the UK
    • 6.9.5. Severity-Specific Cases of Sjogren's syndrome in the United Kingdom
  • 6.10. Japan
    • 6.10.1. Assumptions and Rationale
    • 6.10.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Japan
    • 6.10.3. Gender-Specific Cases of Sjogren's syndrome in Japan
    • 6.10.4. Type-Specific Cases of Sjogren's syndrome in Japan
    • 6.10.5. Severity-Specific Cases of Sjogren's syndrome in Japan

7. Current Treatment Practices

  • 7.1. United States Treatment Guidelines for Sjogren's Disease
  • 7.2. Evidence-based medicine clinical practice guidelines (US, EU, JP)

8. Unmet Needs

9. SWOT Analysis

10. KOL Views

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

List of Tables

  • Table 1: American-European Consensus Group Criteria- Revised international classification criteria for Sjogren's syndrome
  • Table 2: Revised rules for classification - American-European Consensus Group Criteria
  • Table 3: ACR/EULAR criteria
  • Table 4: Selected Non-HLA genes implicated in SS
  • Table 5: Biomarkers in Primary Sjogren's syndrome
  • Table 6: Diagnostic tests to evaluate sicca symptoms in patients with Sjogren's Syndrome
  • Table 7: Evaluation of Dry Eye
  • Table 8: Comparison of the Revised AECG Classification criteria and the ACR Classification criteria for Sjogren's syndrome
  • Table 9: Diagnosed Prevalent Patient Population of Sjogren's syndrome in 7MM (2017-2030)
  • Table 10: Diagnosed Prevalent Cases of Sjogren's syndrome in the US (2017-2030)
  • Table 11: Gender-specific cases of Sjogren's syndrome in the US (2017-2030)
  • Table 12: Type-specific Cases of Sjogren's syndrome in the US (2017-2030)
  • Table 13: Severity specific Cases of Sjogren's syndrome in the United States (2017-2030)
  • Table 14: Diagnosed Prevalent Cases of Sjogren's syndrome in Germany (2017-2030)
  • Table 15: Gender-specific cases of Sjogren's syndrome in Germany (2017-2030)
  • Table 16: Type-specific Cases of Sjogren's syndrome in Germany (2017-2030)
  • Table 17: Severity specific Cases of Sjogren's syndrome in Germany (2017-2030)
  • Table 18: Diagnosed Prevalent Cases of Sjogren's syndrome in France (2017-2030)
  • Table 19: Gender-specific cases of Sjogren's syndrome in France (2017-2030)
  • Table 20: Type-specific Cases of Sjogren's syndrome in France (2017-2030)
  • Table 21: Severity specific Cases of Sjogren's syndrome in France (2017-2030)
  • Table 22: Diagnosed Prevalent Cases of Sjogren's syndrome in Italy (2017-2030)
  • Table 23: Gender-specific cases of Sjogren's syndrome in Italy (2017-2030)
  • Table 24: Type-specific Cases of Sjogren's syndrome in Italy (2017-2030)
  • Table 25: Severity specific Cases of Sjogren's syndrome in Italy (2017-2030)
  • Table 26: Diagnosed Prevalent Cases of Sjogren's syndrome in Spain (2017-2030)
  • Table 27: Gender-specific cases of Sjogren's syndrome in Spain (2017-2030)
  • Table 28: Type-specific Cases of Sjogren's syndrome in Spain (2017-2030)
  • Table 29: Severity specific Cases of Sjogren's syndrome in Spain (2017-2030)
  • Table 30: Diagnosed Prevalent Cases of Sjogren's syndrome in the UK (2017-2030)
  • Table 31: Gender-specific cases of Sjogren's syndrome in the UK (2017-2030)
  • Table 32: Type-specific Cases of Sjogren's syndrome in the UK (2017-2030)
  • Table 33: Severity specific Cases of Sjogren's syndrome in the UK (2017-2030)
  • Table 34: Diagnosed Prevalent Cases of Sjogren's syndrome in Japan (2017-2030)
  • Table 35: Gender-specific cases of Sjogren's syndrome in Japan (2017-2030)
  • Table 36: Type-specific Cases of Sjogren's syndrome in Japan (2017-2030)
  • Table 37: Severity specific Cases of Sjogren's syndrome in Japan (2017-2030)

List of Figures

  • Figure 1: Clinical spectrum Sjogren's syndrome
  • Figure 2: The Pathogenesis of autoimmune epitelitis as a potential explanation for Sjogren's Syndrome
  • Figure 3: Interplay of immune and non-immune factors in the pathophysiology of Sjogren's Syndrome
  • Figure 4: Diagnosed Prevalent Patient Population of Sjogren's syndrome in 7MM (2017-2030)
  • Figure 5: Diagnosed Prevalent Cases of Sjogren's syndrome in the United States (2017-2030)
  • Figure 6: Gender-specific Diagnosed Prevalent Cases of Sjogren's syndrome in the US (2017-2030)
  • Figure 7: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in the US (2017-2030)
  • Figure 8: Severity-specific Cases of Sjogren's syndrome in the US (2017-2030)
  • Figure 9: Diagnosed Prevalent Cases of Sjogren's syndrome in Germany (2017-2030)
  • Figure 10: Gender-specific of Sjogren's syndrome in Germany (2017-2030)
  • Figure 11: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Germany (2017-2030)
  • Figure 12: Severity specific Cases of Sjogren's syndrome in Germany (2017-2030)
  • Figure 13: Diagnosed Prevalent Cases of Sjogren's syndrome in France (2017-2030)
  • Figure 14: Gender-specific Cases of Sjogren's syndrome in France (2017-2030)
  • Figure 15: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in France (2017-2030)
  • Figure 16: Severity specific Cases of Sjogren's syndrome in France (2017-2030)
  • Figure 17: Diagnosed Prevalent Cases of Sjogren's syndrome in Italy (2017-2030)
  • Figure 18: Gender-specific Cases of Sjogren's syndrome in Italy (2017-2030)
  • Figure 19: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Italy (2017-2030)
  • Figure 20: Severity specific Cases of Sjogren's syndrome in Italy (2017-2030)
  • Figure 21: Diagnosed Prevalent Cases of Sjogren's syndrome in Spain (2017-2030)
  • Figure 22: Gender-specific Cases of Sjogren's syndrome in Spain (2017-2030)
  • Figure 23: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Spain (2017-2030)
  • Figure 24: Severity specific Cases of Sjogren's syndrome in Spain (2017-2030)
  • Figure 25: Diagnosed Prevalent Cases of Sjogren's syndrome in the United Kingdom (2017-2030)
  • Figure 26: Gender-specific Cases of Sjogren's syndrome in the United Kingdom (2017-2030)
  • Figure 27: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in the UK (2017-2030)
  • Figure 28: Severity specific Cases of Sjogren's syndrome in the UK (2017-2030)
  • Figure 29: Diagnosed Prevalent Cases of Sjogren's syndrome in Japan (2017-2030)
  • Figure 30: Gender-specific Cases of Sjogren's syndrome in Japan (2017-2030)
  • Figure 31: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Japan (2017-2030)
  • Figure 32: Severity -specific Cases of Sjogren's syndrome in Japan (2017-2030)
  • Figure 33: Unmet Needs of Sjogren's syndrome